Virtual Symposium - The Nexus of Narcolepsy and Cardiometabolic Risk: Important Considerations and Implications for Management

Several cardiometabolic comorbidities, including overweight/obesity, dyslipidemia, cardiovascular diseases, hypertension, and type 2 diabetes or insulin resistance, are common in patients with narcolepsy.  Often these disorders are overlooked, but they have important implications in the management of  these patients.  Some medications used to treat symptoms of narcolepsy may have potential negative effects on cardiovascular health, including in patients that are sensitive to sodium, such as those with hypertension, heart failure, or impaired renal function.  However, long-term data on the cardiovascular safety of narcolepsy treatments are generally lacking. Given these gaps, clinicians would benefit from additional education on how to screen, identify, and better tailor the management of narcolepsy in these patients.

Target Audience

This activity is designed for neurologists, primary care physicians, sleep disorder specialists, physician assistants, nurse practitioners, nurses, registered dieticians, pharmarcists, and other healthcare professionals caring for patients in general and those with sleep disorders.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize that cardiometabolic risk factors are common in patients with narcolepsy 
  • Describe the pathophysiological connections between narcolepsy and increased cardiometabolic risk
  • Review the rationale and evidence behind the increased cardiometabolic risk and risk for major adverse cardiovascular events with commonly-used narcolepsy agents
  • Summarize recent updates with new and emerging narcolepsy treatments 
  • Develop individualized treatment plans for patients with narcolepsy that aim to address EDS, cataplexy, and improve quality of life, while also incorporating strategies to reduce overall cardiometabolic risk and daily sodium intake
Course summary
Available credit: 
  • 1.75 ACPE Pharmacy
  • 1.75 AMA PRA Category 1 Credit
  • 1.75 ANCC
  • 1.75 CDE
  • 1.75 Participation
Course opens: 
Course expires: 

Virend K. Somers, MD, PhD (Chair)
Alice Sheets Marriott Professor
Mayo Clinic and Mayo Foundation
Rochester,  MN

Dr. Somers discloses the following:

Royalty: Preventice
Consulting Fees: Sleep Number, Jazz Pharma, Baker Tilly, Respicardia, Bayer


Board Certified in Cardiology, Nuclear Cardiology and Sleep Medicine
President, Empire Sleep Medicine
Founder, American Academy of Cardiovascular Sleep Medicine

Dr. Surkin discloses the following:

Consulting Fees: Jazz Pharmaceuticals


Phyllis C. Zee, MD, PhD
Professor of Neurology
Northwestern University Feinberg School of Medicine
Director, Sleep Disorders Center
Northwestern Memorial Hospital
Chicago, IL

Dr. Zee discloses the following:

Consulting Fees: Eisai, Jazz, Harmony, CVS Caremark
Contracted Research: Vanda, Harmony
Ownership Interest less than 5%: Teva (stock ownership)


1.75 hours

This activity is supported by educational funding provided by Jazz Pharmaceuticals, Inc.


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.75 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.

Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (.175 CEUs) of the Accreditation Council for Pharmacy Education.

This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-21-3008-H01-P.

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

This program offers 1.75 CPEUs for dieticians.

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

During the period September 20, 2021 through September 20, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at

For questions about the accreditation of this activity, please visit

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.75 ACPE Pharmacy
  • 1.75 AMA PRA Category 1 Credit
  • 1.75 ANCC
  • 1.75 CDE
  • 1.75 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.